Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in IgA Nephropathy
NCT04905212Phase 2Terminated
- Sponsor
- RemeGen
- Start
- Nov 2021
- Primary completion
- Nov 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of telitacicept in IgA nephropathy (IgAN) (3 arms), sponsored by RemeGen. Primary endpoint: Change from baseline in 24-hour urine protein at Week 24. Started Nov 2021; status: terminated.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT04905212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905212.